Archives

  • Meiji Seika and Eisai Enter into a Collaboration for the Development and Commercialization of Safinamide in Parkinson’s Disease for Japan and Asia

    Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; CEO: Daikichiro Kobayashi, “Meiji”) announced today that they have

    Read More

    Archive

    Offers
    error: Content is protected !!